Please wait a minute...
Clinical and Experimental Obstetrics & Gynecology  2014, Vol. 41 Issue (1): 58-61    DOI: 10.12891/ceog16312014
Original Research Previous articles | Next articles
Effect of HbA1C detection on the diagnostic screening for glucose metabolic disorders in polycystic ovary syndrome
Yueqiao Zhen1, *(), Peng Yang2, Ruihong Dong1, Yumin Wu1, Yanhong Sang1, Xiaoxiao Du1, Yan Wang1, Qiuyan Song1, Ling Yu1, Xiaojuan Rao1
1Department of Endocrinology and Metabolism, The Fifth Affiliated Hospital of Zhengzhou University, Zhengzhou
2Department of Endocrinology and Metabolism, Shanghai Tenth People's Hospital, affiliated to Tongji University, Shanghai (China)
Download:  PDF(59KB)  ( 8 )
Export:  BibTeX | EndNote (RIS)      
Abstract  
Purpose: This study aimed to assess the effect of hemoglobin A1C (HbA1C) detection on the diagnostic screening for glucose metabolic disorders in women with polycystic ovary syndrome (PCOS). Materials and Methods: A total of 161 patients with PCOS (mean age = 23.68 ± 4.23 years) were subjected to an oral glucose tolerance test (OGTT). The receiver operating characteristic (ROC) curve was plotted to evaluate the fasting plasma glucose (FPG), and HbA1C was used to probe the sensitivity and specificity of abnormal glucose tolerance. Results: Based on the traditional standards of blood sugar, the prevalence of type 2 diabetes was 5.6%, and the pre-diabetes prevalence was 7.5%. Based on the HbA1C standards, 4.3% of patients were diagnosed with type 2 diabetes, and 10.6% of the diabetic patients can be considered as high-risk populations. Based on the combined standards of OGTT and HbA1C, the prevalence of type 2 diabetes was 6.2%, and the pre-diabetes prevalence was 12.4%. OGTT is considered the gold standard for identifying abnormal glucose tolerance, and HbA1C detection is considered to be stronger than FPG. The areas under the ROC curves of HbA1C and FPG were 0.968 and 0.672, respectively (p < 0.01). The American Diabetes Association (ADA) recommends the cut-off value of HbAlc ≥ 5.7% and FPG ≥ 5.6 mmol/l for identifying abnormal glucose tolerance. The sensitivity and specificity were 76.7% and 89.5% for HBA1C, as well as 40.5% and 94.3% for FPG, respectively. The positive and negative likelihood ratios were 7.3 and 0.26 for HbA1C, as well as 7.1 and 0.63 for FPG, respectively. Conclusion: HbA1C detection can be used as a method for diagnosis and screening.
Key words:  Polycystic ovary syndrome      Oral glucose tolerance test      Receiver operating characteristic curve     
Published:  10 February 2014     
*Corresponding Author(s):  Y. ZHEN     E-mail:  zhenyueqiao@eyou.com

Cite this article: 

Yueqiao Zhen, Peng Yang, Ruihong Dong, Yumin Wu, Yanhong Sang, Xiaoxiao Du, Yan Wang, Qiuyan Song, Ling Yu, Xiaojuan Rao. Effect of HbA1C detection on the diagnostic screening for glucose metabolic disorders in polycystic ovary syndrome. Clinical and Experimental Obstetrics & Gynecology, 2014, 41(1): 58-61.

URL: 

https://ceog.imrpress.com/EN/10.12891/ceog16312014     OR     https://ceog.imrpress.com/EN/Y2014/V41/I1/58

[1] Chang Liu, Minchen Dai, Lei Zhao, Fangfang Wang. The effects of Chinese herbal medicine on the pregnancy outcomes of infertile women with polycystic ovary syndrome undergoing in vitro fertilization-embryo transfer: a systematic review and meta-analysis[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(5): 1032-1043.
[2] Zhenzhen Lu, Ying Gao. Searching for biomarkers in the progression from polycystic ovary syndrome to endometrial carcinoma[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(5): 1117-1125.
[3] Gonca Özten Dere, Esra Uyanik, Fatih Aktoz, Pınar Çalış, Sezcan Mümüşoğlu, Hakan Yarali, Gürkan Bozdağ. The effect of laparoscopic ovarian drilling on timing of menopause in patients with polycystic ovary syndrome: 29 years of follow-up data[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(3): 590-593.
[4] Hye Won Lee, Lin Ang, Myeong Soo Lee, Kyoung Sun Park, Jin-Moo Lee, Chang-Hoon Lee, Dong Chul Kim, Jeong-Eun Yoo, Seung-Jeong Yang, Tae-Young Choi. Prescription patterns of herbal medicine for polycystic ovarian syndrome in major Korean medicine hospitals: a multicenter retrospective study[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(3): 649-653.
[5] J. Dun, X. Wang, J. Yang, J. Xu. Clinical practice guidelines on polycystic ovary syndrome: a systematic review and comparative meta-analysis[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(4): 465-471.
[6] Xiao-Tao Huang, Shao-Rong Liang, Lu Wang. Acupuncture combined with Chinese and western medicine in the treatment of polycystic ovary syndrome[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(3): 396-400.
[7] A. M. Maysara, A. T. Nassar, H. K. Jubran. The effect of correction of serum level of vitamin D on hyperandrogenism in women with polycystic ovary syndrome and hypovitaminosis D[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(2): 272-276.
[8] H.M.G. Youssef, E.S. Marei, L.A. Rashed. Long non-coding RNA steroid receptor activator in polycystic ovary syndrome: possible association with metabolic syndrome[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(5): 757-762.
[9] M.H. Vieira de Melo, M.T. Albuquerque Barbosa Cabral Micussi, R. Dias de Medeiros, R. Ney Cobucci, T.M. de Oliveira Maranhão, A.K. Gonçalves. Pelvic floor muscle thickness in women with polycystic ovary syndrome[J]. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(6): 813-816.
[10] Hui-lan Wang, Xia Xu, Zhi-qun Zheng. The expression of Nuclear Factor-κB in a rat model of polycystic ovary syndrome[J]. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(2): 276-279.
[11] P. Marques, F. Ferreira, A. P. Soares, J. Nunes, S. Sousa, A. Aguiar, C. Calhaz-Jorge. Clinico-biochemical characteristics of 229 Portuguese infertile women with polycystic ovary syndrome: clinical relevance and relationship with fertility treatment results[J]. Clinical and Experimental Obstetrics & Gynecology, 2016, 43(6): 812-817.
[12] L. H. Sordia-Hernández, P. Ancer Rodríguez, D. Saldivar Rodriguez, S. Trejo Guzmán, E. S. Servín Zenteno, G. Guerrero González, R. Ibarra Patiño. Effect of a low glycemic diet in patients with polycystic ovary syndrome and anovulation - a randomized controlled trial[J]. Clinical and Experimental Obstetrics & Gynecology, 2016, 43(4): 555-559.
[13] S. Hacivelioglu, A. Uysal, A.N. Cakir Gungor, M. Gencer, D.U. Cakir, E. Cosar. The effect of maternal polycystic ovary morphology on first-trimester maternal serum biochemical markers of aneuploidy and fetal nuchal translucency thickness[J]. Clinical and Experimental Obstetrics & Gynecology, 2015, 42(1): 32-35.
[14] W. Li, Y. Chen, L. Xu. Association of sympathetic nervous system activity with polycystic ovarian syndrome[J]. Clinical and Experimental Obstetrics & Gynecology, 2014, 41(5): 499-506.
[15] L. Hu, H. Shen, Q.F. Wu, L. Tian, M.H. Hu. Treatment of polycystic ovarian syndrome with insulin resistance by insulin-sensitizer[J]. Clinical and Experimental Obstetrics & Gynecology, 2014, 41(3): 288-292.
No Suggested Reading articles found!